116 results
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
19 Mar 24
Tempest Reports Year End 2023 Financial Results and Provides Business Update
4:10pm
. The increase was primarily due to proceeds from the issuance of common stock of $35.6 million from the at-the-market offering program, offset by cash used
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
8 Nov 23
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
5:18pm
vendors, partially offset by an increase in facilities expenses.
General and administrative expenses for the nine months ended September 30, 2023 were
8-K
EX-99.1
ajdlojtlfy7y
10 Aug 23
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
4:27pm
8-K
EX-99.1
ifa3fxwbddkuf3nx2s
10 May 23
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
4:21pm
8-K
EX-99.1
2btsu5bcz2des0 8w
8 Nov 22
Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
8:55am
8-K
EX-99.1
vqcdxs
15 Aug 22
Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update
8:05am
8-K
EX-10.1
1l1p8a12k3u3dry9lo1
21 Jun 22
Departure of Directors or Certain Officers
7:31am